Compared to SSTR, the role of CXCR4 has been studied more recently in lymphomas, especially in DLBCL, where CXCR4 upregulation has been shown to be associated with tumor cell dissemination, disease progression, and poor survival (14, 18, 22) and also with impaired response to rituximab treatment (23). The gene discussed is CXCR4; the disease is lymphoma.